Download these slides from a CCO Live Webinar to review the latest clinical data novel antibody-drug conjugates for the treatment of NSCLC.
Download these slides from a live CCO Webinar to review the latest clinical trial data on ADCs in NSCLC, including activity in HER2-amplified or mutant lung cancers, as well as in HER3-expressing, EGFR-mutatant NSCLC.
Download these slides from a live CCO Webinar to review the latest clinical trial data on anti–TROP-2, anti-CEACAM, and anti–c-MET ADCs in lung cancer, including ongoing trials evaluating ADC combinations with immunotherapy or third-generation EGFR TKIs.
Download this short summary slideset summarizing clinical trial data presented at a live CCO Webinar featuring expert discussion on the increasing role of antibody-drug conjugates in advanced NSCLC.
Watch this on-demand webcast from a live webinar where experts discuss the latest clinical trial data and their thoughts on the potential for antibody–drug conjugates in the care of patients with advanced NSCLC.
Are antibody drug conjugates a true targeted therapy for NSCLC? Read my thoughts on why I believe ADCs are a great therapeutic option for patients with advanced NSCLC.